MGF

MGF (mechano‑growth factor) is a stress‑responsive splice variant of the insulin‑like growth factor 1 (IGF‑1) gene Role of Alternatively Spliced Messenger RNA (mRNA) Isoforms of the Insulin-Like Growth Factor 1 (IGF1) in Selected Human Tumors+1. Unlike the circulating form of IGF‑1, MGF is produced locally when tissues are mechanically loaded, injured, or starved of oxygen Minireview: Mechano-growth factor: a putative product of IGF-I gene expression involved in tissue repair and regeneration+1. It carries a unique E‑domain tail that allows it to signal through pathways distinct from the classic IGF‑1 receptor Minireview: Mechano-growth factor: a putative product of IGF-I gene expression involved in tissue repair and regeneration.

Preclinical studies have explored MGF’s potential in tissue repair and regeneration. The compound is most often investigated as a synthetic E‑domain peptide rather than the full‑length protein The E-domain region of mechano-growth factor inhibits cellular apoptosis and preserves cardiac function during myocardial infarction. Key areas of research include:

• Cardiac protection after myocardial infarction The E-domain region of mechano-growth factor inhibits cellular apoptosis and preserves cardiac function during myocardial infarction+1
• Cartilage preservation and osteoarthritis models Pretreatment with mechano growth factor E peptide attenuates osteoarthritis through improving cell proliferation and extracellular matrix synthesis in chondrocytes under severe hypoxia+1
• Ligament and tendon healing (e.g., ACL repair) Mechano Growth Factor Accelerates ACL Repair and Improves Cell Mobility of Mechanically Injured Human ACL Fibroblasts by Targeting Rac1-PAK1/2 and RhoA-ROCK1 Pathways
• Bone healing and osteogenesis Mechano-growth factor accelerates the proliferation and osteogenic differentiation of rabbit mesenchymal stem cells through the PI3K/AKT pathway+1
• Neuroprotection and neural stem cell activation Mechano growth factor, a splice variant of IGF-1, promotes neurogenesis in the aging mouse brain+2

Importantly, MGF’s effects are context‑dependent. While it generally promotes cell survival and migration, some studies have noted pro‑inflammatory signaling in muscle injury Overexpression of Mechano-Growth Factor Modulates Inflammatory Cytokine Expression and Macrophage Resolution in Skeletal Muscle Injury and potential growth‑promoting activity in certain cancer cells Preferential expression of IGF‐1Ec (MGF) transcript in cancerous tissues of human prostate: Evidence for a novel and autonomous growth factor activity of MGF E peptide in human prostate cancer cells+1. All evidence remains preclinical; no human therapeutic trials have been reported Minireview: Mechano-growth factor: a putative product of IGF-I gene expression involved in tissue repair and regeneration+1.

MGF’s primary mode of action relies on its unique E‑domain peptide, which can signal through pathways that are largely independent of the classic IGF‑1 receptor Minireview: Mechano-growth factor: a putative product of IGF-I gene expression involved in tissue repair and regeneration+1. This means it can activate cellular repair programs without engaging the same receptor that insulin‑like growth factor 1 uses Preferential expression of IGF‐1Ec (MGF) transcript in cancerous tissues of human prostate: Evidence for a novel and autonomous growth factor activity of MGF E peptide in human prostate cancer cells.

Core signaling pathways

• MAPK/ERK pathway: MGF stimulates cell migration, proliferation, and adhesion in connective tissue cells (e.g., tenocytes, ACL fibroblasts) via ERK1/2 activation Mechano Growth Factor Accelerates ACL Repair and Improves Cell Mobility of Mechanically Injured Human ACL Fibroblasts by Targeting Rac1-PAK1/2 and RhoA-ROCK1 Pathways+1. It also promotes osteoblast proliferation through this route Splicing factor-modulated generation of mechano growth factor regulates physiological processes in osteoblasts under mechanical stimuli.
• PI3K/AKT/mTOR pathway: In mesenchymal stem cells and chondrocytes, MGF turns on the AKT‑mTOR survival axis, boosting proliferation and new tissue matrix production Mechano-growth factor accelerates the proliferation and osteogenic differentiation of rabbit mesenchymal stem cells through the PI3K/AKT pathway+1.

Other important actions

• Anti‑apoptotic effects: MGF reduces programmed cell death in stressed heart muscle, disc cells, and neurons by lowering caspase activation and preserving mitochondrial function The E-domain region of mechano-growth factor inhibits cellular apoptosis and preserves cardiac function during myocardial infarction+2.
• Nucleolin binding: In nerve cells, MGF interacts with the protein nucleolin to enter the nucleus and protect against damage, revealing an intracellular signaling role Mechano growth factor interacts with nucleolin to protect against cisplatin-induced neurotoxicity.
• Mechanotransduction: MGF is produced in response to mechanical load and then feeds forward into migration and survival signaling through RhoA/YAP and Rac1/PAK pathways Mechano Growth Factor Accelerates ACL Repair and Improves Cell Mobility of Mechanically Injured Human ACL Fibroblasts by Targeting Rac1-PAK1/2 and RhoA-ROCK1 Pathways+1.
• Immune modulation: Effects on inflammation are complex; MGF can delay macrophage resolution in injured muscle, which may prolong or reshape the inflammatory response depending on the setting Overexpression of Mechano-Growth Factor Modulates Inflammatory Cytokine Expression and Macrophage Resolution in Skeletal Muscle Injury.

Overall, MGF behaves as a local damage‑control signal that activates multiple repair‑oriented pathways, but the precise balance of its effects varies by tissue type and the nature of the injury Mechano-Growth Factor: an important cog or a loose screw in the repair machinery?+1.

The research literature describes several consistent effects of MGF, all at the preclinical stage.

Tissue repair and regeneration

• Cartilage and osteoarthritis: In animal models, MGF improved chondrocyte survival, boosted cartilage matrix production, and slowed joint degeneration Pretreatment with mechano growth factor E peptide attenuates osteoarthritis through improving cell proliferation and extracellular matrix synthesis in chondrocytes under severe hypoxia+2.
• Ligament and tendon healing: MGF accelerated ACL repair in rabbits and increased migration and adhesion of human ligament fibroblasts under mechanical injury Mechano Growth Factor Accelerates ACL Repair and Improves Cell Mobility of Mechanically Injured Human ACL Fibroblasts by Targeting Rac1-PAK1/2 and RhoA-ROCK1 Pathways.
• Cardiac protection: After experimentally induced heart attacks, MGF‑E peptide reduced cell death, preserved heart function, and limited adverse remodeling in mice The E-domain region of mechano-growth factor inhibits cellular apoptosis and preserves cardiac function during myocardial infarction+2.
• Bone healing: MGF stimulated osteoblast proliferation and enhanced bone defect repair in rabbit models Mechano-growth factor accelerates the proliferation and osteogenic differentiation of rabbit mesenchymal stem cells through the PI3K/AKT pathway+1.

Neuroprotection and neurogenesis

• In aging mice, MGF increased the growth of new neurons in brain regions linked to memory and smell Mechano growth factor, a splice variant of IGF-1, promotes neurogenesis in the aging mouse brain.
• It protected sensory neurons from chemotherapy‑induced damage (cisplatin) through a nucleolin‑dependent mechanism Mechano growth factor interacts with nucleolin to protect against cisplatin-induced neurotoxicity and improved motor neuron survival in an ALS model Mechano-growth factor, an IGF-I splice variant, rescues motoneurons and improves muscle function in SOD1(G93A) mice.

Stem cell recruitment

• MGF (especially the E‑domain) promoted migration of human mesenchymal stem cells, making it a candidate for tissue‑engineering scaffolds Migration and proliferation of human mesenchymal stem cells is stimulated by different regions of the mechano-growth factor prohormone+1.

Cancer‑related caution

• MGF expression is elevated in prostate and colorectal cancer tissues, and exogenous peptide can stimulate proliferation of some cancer cells in culture Preferential expression of IGF‐1Ec (MGF) transcript in cancerous tissues of human prostate: Evidence for a novel and autonomous growth factor activity of MGF E peptide in human prostate cancer cells+2. This raises a safety concern for long‑term or unsupervised use.

All of these effects have been observed only in cell cultures, animal models, or human tissue samples. No controlled human efficacy trials exist Minireview: Mechano-growth factor: a putative product of IGF-I gene expression involved in tissue repair and regeneration+1.

Research protocols for MGF vary widely because no human therapeutic standard exists. Most published studies use local or systemic peptide delivery in animal models, while community practice has developed extrapolated dosing regimens.

Preclinical study regimens

• Cardiac repair (mice): Peptide delivered via intramyocardial microrods or systemic injection shortly after heart attack, with effects measured over 2–10 weeks Localized Delivery of Mechano-Growth Factor E-domain Peptide via Polymeric Microstructures Improves Cardiac Function following Myocardial Infarction+1.
• Cartilage/OA models (rabbits): Intra‑articular doses of 0.1–10 μg/mL or local exposure of 10–60 ng/mL in cell culture; repeated treatments over 2 weeks Pretreatment with mechano growth factor E peptide attenuates osteoarthritis through improving cell proliferation and extracellular matrix synthesis in chondrocytes under severe hypoxia+1.
• Ligament repair (rabbits, human cells): Local peptide at 10 ng/mL or 100 ng/mL; assessed after 24 h (cells) or 2–4 weeks (animal) Mechano Growth Factor Accelerates ACL Repair and Improves Cell Mobility of Mechanically Injured Human ACL Fibroblasts by Targeting Rac1-PAK1/2 and RhoA-ROCK1 Pathways.
• Bone healing (rabbits): MGF‑E peptide applied locally; healing assessed over several weeks Mechano growth factor E peptide promotes osteoblasts proliferation and bone-defect healing in rabbits.

Community‑based protocols (research context)

In the absence of clinical guidelines, practitioners have adopted certain patterns based on the peptide’s short half‑life and tissue‑specific signaling. These are not evidence‑based standards but are commonly referenced:

• Local soft‑tissue repair: 100–300 mcg injected subcutaneously near the injury site, once or twice daily, for 2–6 weeks.
• Systemic recovery: 200–500 mcg subcutaneously, once daily, for 3–6 weeks.
• Exercise‑linked recovery: 100–200 mcg after training sessions, for 4–8 weeks.

Weight‑based scaling often used: 2–5 mcg/kg per dose. Example: for a 70 kg person, a 3 mcg/kg dose equals 210 mcg (rounded to 200–225 mcg).

Because MGF signaling is tied to mechanical stress and injury, timing dosing close to training or tissue loading is thought to be more relevant than clock time Minireview: Mechano-growth factor: a putative product of IGF-I gene expression involved in tissue repair and regeneration+1.

MGF can alter several biological pathways, so it may interact with drugs and supplements that affect growth, inflammation, or apoptosis.

Drug interactions

• Chemotherapy (especially cisplatin): MGF protected neurons from cisplatin toxicity in animal models Mechano growth factor interacts with nucleolin to protect against cisplatin-induced neurotoxicity. While this might preserve nerve function, it is unknown whether it interferes with tumor‑killing effects.
• Cancer drugs that rely on apoptosis: Because MGF is anti‑apoptotic and can promote cancer cell growth in some models Preferential expression of IGF‐1Ec (MGF) transcript in cancerous tissues of human prostate: Evidence for a novel and autonomous growth factor activity of MGF E peptide in human prostate cancer cells+1, using it alongside chemotherapy could theoretically reduce intended cell death. Avoid in active cancer.
• Anabolic/androgenic agents and GH/IGF‑1 axis drugs: MGF and androgens share overlapping anabolic signaling Androgen-mediated improvement of body composition and muscle function involves a novel early transcriptional program including IGF1, mechano growth factor, and induction of β-catenin. Additive effects on tissue growth and water retention are possible; monitor for edema and cardiovascular stress.
• Cardiovascular medications: MGF can directly influence heart contractility in mice Mechano-growth factor E-domain modulates cardiac contractile function through 14-3-3 protein interactomes, so patients with heart conditions should be cautious.

Supplement interactions

• Growth‑promoting supplements (creatine, EAAs, HMB): Likely complementary for recovery, but no direct studies with MGF exist. Watch for excessive muscle pump or compartment tightness.
• Strong antioxidants (NAC, quercetin): May reinforce MGF’s cytoprotective Nrf2/HO‑1 signaling C‐terminal mechano‐growth factor induces heme oxygenase‐1‐mediated neuroprotection of SH‐SY5Y cells via the protein kinase Cϵ/Nrf2 pathway; potentially beneficial for recovery but could be unwanted during chemotherapy.
• Anti‑inflammatory botanicals (high‑dose curcumin, boswellia): MGF’s effects on inflammation are context‑dependent; strong anti‑inflammatories might blunt some adaptive repair signaling Overexpression of Mechano-Growth Factor Modulates Inflammatory Cytokine Expression and Macrophage Resolution in Skeletal Muscle Injury.

Condition‑specific caution

• Active or recent cancer: Strongest caution due to documented proliferative signals in prostate, osteosarcoma, and colorectal models Preferential expression of IGF‐1Ec (MGF) transcript in cancerous tissues of human prostate: Evidence for a novel and autonomous growth factor activity of MGF E peptide in human prostate cancer cells+2.
• Precancerous conditions (BPH, endometriosis): Theoretical risk of growth promotion Insulinlike Growth Factor-1Ec (MGF) Expression in Eutopic and Ectopic Endometrium: Characterization of the MGF E-Peptide Actions In Vitro.
• Heart disease: MGF’s cardiac effects are dose‑sensitive and non‑linear; self‑experimentation is risky Mechano-growth factor E-domain modulates cardiac contractile function through 14-3-3 protein interactomes.

All interaction data are preclinical or theoretical; no human drug‑interaction studies exist.

MGF is frequently considered in combination with other peptides to target multiple aspects of tissue repair, though evidence for specific stacks is predominantly theoretical or based on community experience.

Synergistic or complementary stacks

• MGF + BPC‑157: Both support connective tissue healing; BPC‑157 promotes angiogenesis and fibroblast migration, while MGF enhances local cell survival and matrix production Mechano Growth Factor Accelerates ACL Repair and Improves Cell Mobility of Mechanically Injured Human ACL Fibroblasts by Targeting Rac1-PAK1/2 and RhoA-ROCK1 Pathways+1. Community practice often pairs them for tendon/ligament injuries.
• MGF + TB‑500 (Thymosin Beta‑4): TB‑500 stimulates cell migration and reduces inflammation, complementing MGF’s proliferative and anti‑apoptotic signals Migration and proliferation of human mesenchymal stem cells is stimulated by different regions of the mechano-growth factor prohormone+1. A common stack for general soft‑tissue recovery.
• MGF + IGF‑1 LR3: The combination targets the IGF‑1 axis more broadly. Since MGF operates partly independently of the IGF‑1 receptor, adding LR3 may amplify anabolic signaling, but also increases edema and growth‑related side‑effect risk Androgen-mediated improvement of body composition and muscle function involves a novel early transcriptional program including IGF1, mechano growth factor, and induction of β-catenin+1.
• MGF + GH secretagogues (e.g., Ipamorelin, CJC‑1295): These elevate endogenous GH and IGF‑1, potentially creating a supportive hormonal environment for MGF’s local repair actions Androgen-mediated improvement of body composition and muscle function involves a novel early transcriptional program including IGF1, mechano growth factor, and induction of β-catenin. Use with caution to avoid excessive water retention or joint pain.

Potentially problematic stacks

• MGF with high‑dose insulin or strong anabolics: The convergence on PI3K/AKT and ERK pathways could drive hypertrophic or fibrotic over‑repair Mechano-growth factor accelerates the proliferation and osteogenic differentiation of rabbit mesenchymal stem cells through the PI3K/AKT pathway+1.
• MGF during active cancer treatment: Any stack that includes anti‑apoptotic or growth‑promoting peptides is contraindicated in cancer Preferential expression of IGF‐1Ec (MGF) transcript in cancerous tissues of human prostate: Evidence for a novel and autonomous growth factor activity of MGF E peptide in human prostate cancer cells+1.

Stacking protocols are not validated in clinical trials. If researching combinations, introduce one compound at a time and document any changes in function, swelling, or systemic symptoms.

MGF is not approved as a medicine by any major regulatory agency. The corpus contains no FDA, EMA, MHRA, or TGA authorization for therapeutic use Minireview: Mechano-growth factor: a putative product of IGF-I gene expression involved in tissue repair and regeneration+1. All evidence supporting its activity comes from preclinical models or analytical characterization of black‑market products Characterization and identification of a C‐terminal amidated mechano growth factor (MGF) analogue in black market products+1.

In the United States, MGF is not listed as a scheduled controlled substance, but it is not recognized as a dietary supplement either. Products labeled as MGF are typically sold through gray‑market channels and may contain amidated analogues or recombinant variants that differ from the endogenous peptide Characterization and identification of a C‐terminal amidated mechano growth factor (MGF) analogue in black market products+1.

Anti‑doping status

MGF is prohibited in sport. The World Anti‑Doping Agency (WADA) has banned MGF and its analogues, and the literature explicitly discusses its relevance to doping controls Characterization and identification of a C‐terminal amidated mechano growth factor (MGF) analogue in black market products+1. Athletes subject to testing should avoid any MGF‑containing product. There is no documented therapeutic use exemption (TUE) pathway.

International considerations

No country‑specific import rules are documented in the research corpus. However, because MGF is frequently associated with black‑market peptide sales, cross‑border shipments may be subject to customs seizure or legal scrutiny.

In summary, MGF exists in a regulatory gray zone: it is not a licensed drug, not a dietary supplement, and explicitly banned in sport.

Human safety data for MGF are essentially absent. All potential risks are extrapolated from animal and cell studies, so any use should be approached with extreme caution.

Known and theoretical risks

• Cancer promotion: MGF can stimulate proliferation, migration, and invasion of prostate and osteosarcoma cells, and its expression is elevated in colorectal tumors Preferential expression of IGF‐1Ec (MGF) transcript in cancerous tissues of human prostate: Evidence for a novel and autonomous growth factor activity of MGF E peptide in human prostate cancer cells+2. The peptide’s anti‑apoptotic bias may also protect malignant cells from natural or treatment‑induced cell death The E-domain region of mechano-growth factor inhibits cellular apoptosis and preserves cardiac function during myocardial infarction+1.
• Cardiac effects: In mice, MGF‑E peptide directly altered heart contractility and, at certain doses, depressed systolic and diastolic function Mechano-growth factor E-domain modulates cardiac contractile function through 14-3-3 protein interactomes. This suggests a narrow therapeutic window.
• Inflammatory modulation: MGF can delay the resolution of pro‑inflammatory macrophages in injured muscle, potentially prolonging inflammation after trauma Overexpression of Mechano-Growth Factor Modulates Inflammatory Cytokine Expression and Macrophage Resolution in Skeletal Muscle Injury.
• Injection site reactions: Community reports include transient swelling, redness, or discomfort at the injection site. No frequency data exist.

Contraindications

• Absolute (should be avoided):
  • Active cancer or any unexplained proliferative lesion
  • Unstable heart disease or significant structural heart abnormalities
  • Pregnancy and breastfeeding (no safety data)
• Relative (use with care):
  • Autoimmune or highly inflammatory conditions
  • Recent surgery or scar‑sensitive areas
  • Concurrent use of other growth factors or anabolic agents

What is unknown

• No human pharmacokinetic, immunogenicity, or long‑term toxicity data exist.
• Safe duration of use is undefined; animal studies rarely exceed 4–8 weeks of exposure The E-domain region of mechano-growth factor inhibits cellular apoptosis and preserves cardiac function during myocardial infarction+2.
• Interaction with common medications is unstudied in humans.

Given these gaps, MGF should be considered a high‑risk experimental compound with a concerning safety signal in oncology.